AXQ Capital’s DiaMedica Therapeutics DMAC Stock Holding History

AXQ Capital’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,070	Closed	-$96.1K	–	1061
2025 Q4	$96.1K	Buy	+12,070	New	+$90.3K	0.02%	658

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AXQ Capital's DMAC Position: Q1 2026 in Review

AXQ Capital sold out of DiaMedica Therapeutics (DMAC) in Q1 2026, closing a stake of 12,070 shares — an estimated $96.1K sold.

AXQ Capital first reported a position in DMAC in Q4 2025 and held it in 1 quarter. The position peaked at $96.1K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

AXQ Capital reported no remaining DiaMedica Therapeutics position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 12,070 DiaMedica Therapeutics shares in Q1 2026, an estimated $96.1K.
AXQ Capital first reported a position in DiaMedica Therapeutics in Q4 2025 and held it in 1 quarter.
AXQ Capital's DiaMedica Therapeutics position peaked at $96.1K in Q4 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.